These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29873684)

  • 1. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
    Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
    Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
    Diefenhardt M; Fleischmann M; Martin D; Hofheinz RD; Piso P; Germer CT; Hambsch P; Grützmann R; Kirste S; Schlenska-Lange A; Ghadimi M; Rödel C; Fokas E;
    Radiother Oncol; 2023 Feb; 179():109455. PubMed ID: 36572280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
    Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
    Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
    Sauer R; Liersch T; Merkel S; Fietkau R; Hohenberger W; Hess C; Becker H; Raab HR; Villanueva MT; Witzigmann H; Wittekind C; Beissbarth T; Rödel C
    J Clin Oncol; 2012 Jun; 30(16):1926-33. PubMed ID: 22529255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
    Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
    Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial.
    Kosmala R; Fokas E; Flentje M; Sauer R; Liersch T; Graeven U; Fietkau R; Hohenberger W; Arnold D; Hofheinz RD; Ghadimi M; Ströbel P; Staib L; Grabenbauer GG; Folprecht G; Kirste S; Uter W; Gall C; Rödel C; Polat B;
    Eur J Cancer; 2021 Feb; 144():281-290. PubMed ID: 33383348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.
    Diefenhardt M; Hofheinz RD; Martin D; Beißbarth T; Arnold D; Hartmann A; von der Grün J; Grützmann R; Liersch T; Ströbel P; Grabenbauer GG; Rieger M; Fietkau R; Graeven U; Weitz J; Folprecht G; Ghadimi M; Rödel F; Rödel C; Fokas E;
    Int J Cancer; 2019 Oct; 145(8):2282-2291. PubMed ID: 30868576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
    Fokas E; Schlenska-Lange A; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Kirste S; Jacobasch L; Allgäuer M; Flentje M; Germer CT; Grützmann R; Hildebrandt G; Schwarzbach M; Bechstein WO; Sülberg H; Friede T; Gaedcke J; Ghadimi M; Hofheinz RD; Rödel C;
    JAMA Oncol; 2022 Jan; 8(1):e215445. PubMed ID: 34792531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
    Fokas E; Ströbel P; Fietkau R; Ghadimi M; Liersch T; Grabenbauer GG; Hartmann A; Kaufmann M; Sauer R; Graeven U; Hoffmanns H; Raab HR; Hothorn T; Wittekind C; Rödel C;
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.
    Fokas E; Allgäuer M; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Schmiegel W; Jacobasch L; Weitz J; Folprecht G; Schlenska-Lange A; Flentje M; Germer CT; Grützmann R; Schwarzbach M; Paolucci V; Bechstein WO; Friede T; Ghadimi M; Hofheinz RD; Rödel C;
    J Clin Oncol; 2019 Dec; 37(34):3212-3222. PubMed ID: 31150315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
    Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
    BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
    JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
    Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
    JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.